Schuurman B, Sirovich I, Heuff G, van der Wilt C L, Peters G J, Beelen R H, Meyer S
Department of Surgical Oncology, Free University Hospital, Amsterdam, The Netherlands.
J Surg Oncol. 1995 Nov;60(3):180-4. doi: 10.1002/jso.2930600308.
The mode of action of the combination treatment 5-fluorouracil (5-FU) and levamisole in colorectal cancer patients is unknown. It is postulated that the beneficial effect may be explained by an immunomodulatory effect on Kupffer cell (KC) cytotoxicity. We evaluated the effect of levamisole (200 micrograms/ml) and 5-FU (10 microM) on rat KC cytotoxicity against syngeneic CC531 tumor cells. Viability of KCs was unaffected by 5-FU and/or levamisole. The combination did not enhance growth inhibition of CC531 compared to 5-FU alone. A significant increase in KC cytotoxicity was observed after 24-hr incubation with 5-FU/levamisole especially at an effector/target ratio of 10 (P < 0.05). 5-FU alone had no effect on KC cytotoxicity, while levamisole induced only a slight increase. Our in vitro data suggest that the additive effect of the combination 5-FU/levamisole on KC cytotoxicity may attribute to the beneficial effect of the adjuvant treatment in colorectal cancer patients.
5-氟尿嘧啶(5-FU)与左旋咪唑联合治疗对结直肠癌患者的作用机制尚不清楚。据推测,其有益效果可能是通过对库普弗细胞(KC)细胞毒性的免疫调节作用来解释的。我们评估了左旋咪唑(200微克/毫升)和5-FU(10微摩尔)对大鼠KC针对同基因CC531肿瘤细胞的细胞毒性的影响。KC的活力不受5-FU和/或左旋咪唑的影响。与单独使用5-FU相比,联合用药并未增强对CC531的生长抑制作用。在与5-FU/左旋咪唑孵育24小时后,观察到KC细胞毒性显著增加,尤其是在效应细胞/靶细胞比例为10时(P<0.05)。单独使用5-FU对KC细胞毒性没有影响,而左旋咪唑仅引起轻微增加。我们的体外数据表明,5-FU/左旋咪唑联合用药对KC细胞毒性的相加作用可能归因于辅助治疗对结直肠癌患者的有益效果。